Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

被引:0
|
作者
Tang, Amber B. [1 ]
Ziaeian, Boback [2 ]
Butler, Javed [3 ,4 ]
Yancy, Clyde W. [5 ]
Fonarow, Gregg C. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Div Cardiol, 10833 LeConte Ave, Los Angeles, CA 90095 USA
[3] Baylor Scott & White Res Inst, Dallas, TX USA
[4] Univ Mississippi, Jackson, MS USA
[5] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
关键词
D O I
10.1001/jamacardio.2024.3023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ImportanceGuideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. ObjectiveTo assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and ParticipantsEstimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and MeasuresAll-cause mortality. ResultsOf an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving beta-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor-neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and RelevanceImprovement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
引用
收藏
页码:1154 / 1158
页数:5
相关论文
共 50 条
  • [1] Implementation of guideline-directed medical therapy for heart failure
    Laufs, Ulrich
    Wachter, Rolf
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (08) : 1715 - 1716
  • [2] Guideline-Directed Medical Therapy Intolerance in Heart Failure
    Ayoola, Adeoluwa
    Ohringer, Alison
    Nguyen, Oanh Kieu
    JAMA INTERNAL MEDICINE, 2024, 184 (12) : 1468 - 1469
  • [3] Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure
    Shahid, Izza
    Khan, Muhammad Shahzeb
    Fonarow, Gregg C.
    Butler, Javed
    Greene, Stephen J.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2024, 82 : 61 - 69
  • [4] Impact of Intensive Guideline-Directed Medical Therapy for Ischemic Heart Failure Outcomes
    Crosier, Rebecca
    Freitas, Cassandra
    Ross, Heather J.
    Lawler, Patrick R.
    Austin, Peter C.
    Ko, Dennis T.
    Stukel, Therese A.
    Farkouh, Michael E.
    Wang, Xuesong
    Spertus, John A.
    Lee, Douglas S.
    CIRCULATION, 2019, 140
  • [5] Implementation of guideline-directed medical therapy for heart failure: Progress achieved, work ahead!
    Abdin, Amr
    Jhund, Pardeep S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (10) : 2258 - 2260
  • [6] Heart failure: how to optimize guideline-directed medical therapy
    Crea, Filippo
    EUROPEAN HEART JOURNAL, 2022, 43 (27) : 2533 - 2537
  • [7] Improving Utilization of Guideline-Directed Medical Therapy for Heart Failure
    Baksh, Gladys
    Haydo, Michele
    Frazier, Suzanne
    Reesor, Heather
    Kunselman, Allen
    Ahmed, Samaa
    Contreras, Carlos
    Ali, Omaima
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2024, 20 (08):
  • [8] Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure
    Thibodeau, Jennifer T.
    Gorodeski, Eiran Z.
    CIRCULATION, 2020, 142 (16) : 1507 - 1509
  • [9] Keeping Score of Heart Failure Guideline-directed Medical Therapy
    DeVore, Adam D.
    Fonarow, Gregg C.
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (11) : 1421 - 1422
  • [10] Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure
    Khan, Muhammad Shahzeb
    Singh, Sumitabh
    Segar, Matthew W.
    Usman, Muhammad Shariq
    Keshvani, Neil
    Ambrosy, Andrew P.
    Fiuzat, Mona
    Van Spall, Harriette G. C.
    Fonarow, Gregg C.
    Zannad, Faiez
    Felker, G. Michael
    Januzzi, James L.
    O'Connor, Christopher
    Butler, Javed
    Pandey, Ambarish
    JACC-HEART FAILURE, 2023, 11 (11) : 1507 - 1517